http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Thu, 16 Jul 2026 16:16:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CASTLE+BIOSCIENCES+INC++++For%3A+Jul+14++Filed+by%3A+MAETZOLD+DEREK+J/26779886.html si-local-file:///var/storage/secattach/20260716/26779886.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CASTLE+BIOSCIENCES+INC++++For%3A+Jul+14++Filed+by%3A+MAETZOLD+DEREK+J/26779886.html Thu, 16 Jul 2026 16:16:00 -0400 CSTL O.26012332 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CASTLE+BIOSCIENCES+INC++++For%3A+Jul+14++Filed+by%3A+MAETZOLD+DEREK+J/26779886.html si-local-file:///var/storage/secattach/20260716/26779886.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CASTLE+BIOSCIENCES+INC++++For%3A+Jul+14++Filed+by%3A+MAETZOLD+DEREK+J/26779886.html Thu, 16 Jul 2026 16:16:00 -0400 CSTL O.26012332 http://www.streetinsider.com/Corporate+News/Castle+Biosciences+wins+New+York+approval+for+atopic+dermatitis+test/26768613.html <p>Castle Biosciences (Nasdaq: CSTL) announced it has received assay approval from the New York State Department of Health's Clinical Laboratory Evaluation Program for its AdvanceAD-Tx test, a non-invasive gene expression profile test designed to guide systemic therapy selection for patients aged 12 and older with moderate-to-severe atopic dermatitis.</p><p>The test analyzes RNA expression data from lesional skin scraping samples — no biopsy required — evaluating 487 genes across 12 inflammatory and cutaneous biology pathways. Results classify patients into one of two molecular profiles: a JAK Inhibitor Responder Profile or a T helper 2 Molecular Profile, intended to help clinicians select a http://www.streetinsider.com/Corporate+News/Castle+Biosciences+wins+New+York+approval+for+atopic+dermatitis+test/26768613.html Tue, 14 Jul 2026 16:30:39 -0400 CSTL http://www.streetinsider.com/Press+Releases/Castle+Biosciences+Announces+New+York+State+Department+of+Health+Approval+of+its+AdvanceAD-Tx%E2%84%A2+Test/26768590.html <div class="xn-content"> <p class="prntac"><i>Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitis</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.friood" idsrc="xmltag.org" >FRIENDSWOOD, Texas</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CSTL" idsrc="xmltag.org" >Castle Biosciences, Inc.</span> (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the <span>New York State Department of Health</span> (NYSDOH) for its AdvanceAD-Tx test. AdvanceAD-Tx is a non-invasive gene expression profile test designed to guide systemic therapy selection for patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD).</p><p>"We http://www.streetinsider.com/Press+Releases/Castle+Biosciences+Announces+New+York+State+Department+of+Health+Approval+of+its+AdvanceAD-Tx%E2%84%A2+Test/26768590.html Tue, 14 Jul 2026 16:30:00 -0400 A.36747586 CSTL O.00036564 O.26012332 http://www.streetinsider.com/Press+Releases/Castle+Biosciences+Announces+New+York+State+Department+of+Health+Approval+of+its+AdvanceAD-Tx%E2%84%A2+Test/26768590.html <div class="xn-content"> <p class="prntac"><i>Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitis</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.friood" idsrc="xmltag.org" >FRIENDSWOOD, Texas</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CSTL" idsrc="xmltag.org" >Castle Biosciences, Inc.</span> (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the <span>New York State Department of Health</span> (NYSDOH) for its AdvanceAD-Tx test. AdvanceAD-Tx is a non-invasive gene expression profile test designed to guide systemic therapy selection for patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD).</p><p>"We http://www.streetinsider.com/Press+Releases/Castle+Biosciences+Announces+New+York+State+Department+of+Health+Approval+of+its+AdvanceAD-Tx%E2%84%A2+Test/26768590.html Tue, 14 Jul 2026 16:30:00 -0400 A.36747586 CSTL O.00036564 O.26012332 http://www.streetinsider.com/Press+Releases/Castle+Biosciences+Announces+New+York+State+Department+of+Health+Approval+of+its+AdvanceAD-Tx%E2%84%A2+Test/26768590.html <div class="xn-content"> <p class="prntac"><i>Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitis</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.friood" idsrc="xmltag.org" >FRIENDSWOOD, Texas</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CSTL" idsrc="xmltag.org" >Castle Biosciences, Inc.</span> (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the <span>New York State Department of Health</span> (NYSDOH) for its AdvanceAD-Tx test. AdvanceAD-Tx is a non-invasive gene expression profile test designed to guide systemic therapy selection for patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD).</p><p>"We http://www.streetinsider.com/Press+Releases/Castle+Biosciences+Announces+New+York+State+Department+of+Health+Approval+of+its+AdvanceAD-Tx%E2%84%A2+Test/26768590.html Tue, 14 Jul 2026 16:30:00 -0400 A.36747586 CSTL O.00036564 O.26012332 http://www.streetinsider.com/Press+Releases/Castle+Biosciences+Announces+New+York+State+Department+of+Health+Approval+of+its+AdvanceAD-Tx%E2%84%A2+Test/26768590.html <div class="xn-content"> <p class="prntac"><i>Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitis</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.friood" idsrc="xmltag.org" >FRIENDSWOOD, Texas</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CSTL" idsrc="xmltag.org" >Castle Biosciences, Inc.</span> (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the <span>New York State Department of Health</span> (NYSDOH) for its AdvanceAD-Tx test. AdvanceAD-Tx is a non-invasive gene expression profile test designed to guide systemic therapy selection for patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD).</p><p>"We http://www.streetinsider.com/Press+Releases/Castle+Biosciences+Announces+New+York+State+Department+of+Health+Approval+of+its+AdvanceAD-Tx%E2%84%A2+Test/26768590.html Tue, 14 Jul 2026 16:30:00 -0400 A.36747586 CSTL O.00036564 O.26012332 http://www.streetinsider.com/PRNewswire/Castle+Biosciences+Announces+New+York+State+Department+of+Health+Approval+of+its+AdvanceAD-Tx%E2%84%A2+Test/26768590.html <div class="xn-content"> <p class="prntac"><i>Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitis</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.friood" idsrc="xmltag.org" >FRIENDSWOOD, Texas</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CSTL" idsrc="xmltag.org" >Castle Biosciences, Inc.</span> (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the <span>New York State Department of Health</span> (NYSDOH) for its AdvanceAD-Tx test. AdvanceAD-Tx is a non-invasive gene expression profile test designed to guide systemic therapy selection for patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD).</p><p>"We http://www.streetinsider.com/PRNewswire/Castle+Biosciences+Announces+New+York+State+Department+of+Health+Approval+of+its+AdvanceAD-Tx%E2%84%A2+Test/26768590.html Tue, 14 Jul 2026 16:30:00 -0400 A.36747586 CSTL O.00036564 O.26012332 http://www.streetinsider.com/PRNewswire/Castle+Biosciences+Announces+New+York+State+Department+of+Health+Approval+of+its+AdvanceAD-Tx%E2%84%A2+Test/26768590.html <div class="xn-content"> <p class="prntac"><i>Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitis</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.friood" idsrc="xmltag.org" >FRIENDSWOOD, Texas</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CSTL" idsrc="xmltag.org" >Castle Biosciences, Inc.</span> (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the <span>New York State Department of Health</span> (NYSDOH) for its AdvanceAD-Tx test. AdvanceAD-Tx is a non-invasive gene expression profile test designed to guide systemic therapy selection for patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD).</p><p>"We http://www.streetinsider.com/PRNewswire/Castle+Biosciences+Announces+New+York+State+Department+of+Health+Approval+of+its+AdvanceAD-Tx%E2%84%A2+Test/26768590.html Tue, 14 Jul 2026 16:30:00 -0400 A.36747586 CSTL O.00036564 O.26012332 http://www.streetinsider.com/PRNewswire/Castle+Biosciences+Announces+New+York+State+Department+of+Health+Approval+of+its+AdvanceAD-Tx%E2%84%A2+Test/26768590.html <div class="xn-content"> <p class="prntac"><i>Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitis</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.friood" idsrc="xmltag.org" >FRIENDSWOOD, Texas</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CSTL" idsrc="xmltag.org" >Castle Biosciences, Inc.</span> (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the <span>New York State Department of Health</span> (NYSDOH) for its AdvanceAD-Tx test. AdvanceAD-Tx is a non-invasive gene expression profile test designed to guide systemic therapy selection for patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD).</p><p>"We http://www.streetinsider.com/PRNewswire/Castle+Biosciences+Announces+New+York+State+Department+of+Health+Approval+of+its+AdvanceAD-Tx%E2%84%A2+Test/26768590.html Tue, 14 Jul 2026 16:30:00 -0400 A.36747586 CSTL O.00036564 O.26012332 http://www.streetinsider.com/PRNewswire/Castle+Biosciences+Announces+New+York+State+Department+of+Health+Approval+of+its+AdvanceAD-Tx%E2%84%A2+Test/26768590.html <div class="xn-content"> <p class="prntac"><i>Approval expands access to Castle's precision medicine test designed to guide systemic treatment decision making in patients with moderate-to-severe atopic dermatitis</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.friood" idsrc="xmltag.org" >FRIENDSWOOD, Texas</location></span>, <span class="legendSpanClass"><chron>July 14, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CSTL" idsrc="xmltag.org" >Castle Biosciences, Inc.</span> (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it has received assay approval from the <span>New York State Department of Health</span> (NYSDOH) for its AdvanceAD-Tx test. AdvanceAD-Tx is a non-invasive gene expression profile test designed to guide systemic therapy selection for patients aged 12 years and older with moderate-to-severe atopic dermatitis (AD).</p><p>"We http://www.streetinsider.com/PRNewswire/Castle+Biosciences+Announces+New+York+State+Department+of+Health+Approval+of+its+AdvanceAD-Tx%E2%84%A2+Test/26768590.html Tue, 14 Jul 2026 16:30:00 -0400 A.36747586 CSTL O.00036564 O.26012332 http://www.streetinsider.com/Analyst+PT+Change/Castle+Biosciences+%28CSTL%29+PT+Lowered+to+%2436+at+Baird/26759704.html Baird analyst Catherine Schulte lowered the price target on Castle Biosciences (NASDAQ: CSTL) to $36.00 (from $43.00) while maintaining a Outperform rating. http://www.streetinsider.com/Analyst+PT+Change/Castle+Biosciences+%28CSTL%29+PT+Lowered+to+%2436+at+Baird/26759704.html Mon, 13 Jul 2026 07:18:06 -0400 CSTL http://www.streetinsider.com/Press+Releases/Castle+Biosciences+to+Release+Second+Quarter+2026+Financial+Results+and+Host+Webcast+on+Thursday%2C+July+30%2C+2026/26749912.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tx.friood" idsrc="xmltag.org" >FRIENDSWOOD, Texas</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CSTL" idsrc="xmltag.org" >Castle Biosciences, Inc.</span> (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended <chron>June 30, 2026</chron>, after the close of market on <chron>Thursday, July 30, 2026</chron>.</p><p>Company management will host a webcast to discuss its financial results at <chron>4:30 p.m. Eastern time</chron> on the same day.</p><p><b>Webcast Details<br /></b>The live webcast can be accessed here: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4727942-1&amp;h=3238963478&amp;u=https%3A%2F%2Fevent.choruscall.com%2Fmediaframe%2Fwebcast.html%3Fwebcastid%3Dgbu0MZxe&amp;a=https%3A%2F%2Fevent.choruscall.com%2Fmediaframe%2Fwebcast.html%3Fwebcastid%3Dgbu0MZxe" target="_blank" rel="nofollow">https://event.choruscall.com/mediaframe/webcast.html?webcastid=gbu0MZxe</a>, or via the webcast link on the Investor Relations http://www.streetinsider.com/Press+Releases/Castle+Biosciences+to+Release+Second+Quarter+2026+Financial+Results+and+Host+Webcast+on+Thursday%2C+July+30%2C+2026/26749912.html Thu, 09 Jul 2026 07:00:00 -0400 CSTL O.26012332 http://www.streetinsider.com/Press+Releases/Castle+Biosciences+to+Release+Second+Quarter+2026+Financial+Results+and+Host+Webcast+on+Thursday%2C+July+30%2C+2026/26749912.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tx.friood" idsrc="xmltag.org" >FRIENDSWOOD, Texas</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CSTL" idsrc="xmltag.org" >Castle Biosciences, Inc.</span> (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended <chron>June 30, 2026</chron>, after the close of market on <chron>Thursday, July 30, 2026</chron>.</p><p>Company management will host a webcast to discuss its financial results at <chron>4:30 p.m. Eastern time</chron> on the same day.</p><p><b>Webcast Details<br /></b>The live webcast can be accessed here: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4727942-1&amp;h=3238963478&amp;u=https%3A%2F%2Fevent.choruscall.com%2Fmediaframe%2Fwebcast.html%3Fwebcastid%3Dgbu0MZxe&amp;a=https%3A%2F%2Fevent.choruscall.com%2Fmediaframe%2Fwebcast.html%3Fwebcastid%3Dgbu0MZxe" target="_blank" rel="nofollow">https://event.choruscall.com/mediaframe/webcast.html?webcastid=gbu0MZxe</a>, or via the webcast link on the Investor Relations http://www.streetinsider.com/Press+Releases/Castle+Biosciences+to+Release+Second+Quarter+2026+Financial+Results+and+Host+Webcast+on+Thursday%2C+July+30%2C+2026/26749912.html Thu, 09 Jul 2026 07:00:00 -0400 CSTL O.26012332 http://www.streetinsider.com/PRNewswire/Castle+Biosciences+to+Release+Second+Quarter+2026+Financial+Results+and+Host+Webcast+on+Thursday%2C+July+30%2C+2026/26749912.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tx.friood" idsrc="xmltag.org" >FRIENDSWOOD, Texas</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CSTL" idsrc="xmltag.org" >Castle Biosciences, Inc.</span> (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended <chron>June 30, 2026</chron>, after the close of market on <chron>Thursday, July 30, 2026</chron>.</p><p>Company management will host a webcast to discuss its financial results at <chron>4:30 p.m. Eastern time</chron> on the same day.</p><p><b>Webcast Details<br /></b>The live webcast can be accessed here: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4727942-1&amp;h=3238963478&amp;u=https%3A%2F%2Fevent.choruscall.com%2Fmediaframe%2Fwebcast.html%3Fwebcastid%3Dgbu0MZxe&amp;a=https%3A%2F%2Fevent.choruscall.com%2Fmediaframe%2Fwebcast.html%3Fwebcastid%3Dgbu0MZxe" target="_blank" rel="nofollow">https://event.choruscall.com/mediaframe/webcast.html?webcastid=gbu0MZxe</a>, or via the webcast link on the Investor Relations http://www.streetinsider.com/PRNewswire/Castle+Biosciences+to+Release+Second+Quarter+2026+Financial+Results+and+Host+Webcast+on+Thursday%2C+July+30%2C+2026/26749912.html Thu, 09 Jul 2026 07:00:00 -0400 CSTL O.26012332 http://www.streetinsider.com/PRNewswire/Castle+Biosciences+to+Release+Second+Quarter+2026+Financial+Results+and+Host+Webcast+on+Thursday%2C+July+30%2C+2026/26749912.html <div class="xn-content"> <p><span class="legendSpanClass"><location value="LU/us.tx.friood" idsrc="xmltag.org" >FRIENDSWOOD, Texas</location></span>, <span class="legendSpanClass"><chron>July 9, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CSTL" idsrc="xmltag.org" >Castle Biosciences, Inc.</span> (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will release its financial results for the second quarter ended <chron>June 30, 2026</chron>, after the close of market on <chron>Thursday, July 30, 2026</chron>.</p><p>Company management will host a webcast to discuss its financial results at <chron>4:30 p.m. Eastern time</chron> on the same day.</p><p><b>Webcast Details<br /></b>The live webcast can be accessed here: <a target="_blank" href="https://edge.prnewswire.com/c/link/?t=0&amp;l=en&amp;o=4727942-1&amp;h=3238963478&amp;u=https%3A%2F%2Fevent.choruscall.com%2Fmediaframe%2Fwebcast.html%3Fwebcastid%3Dgbu0MZxe&amp;a=https%3A%2F%2Fevent.choruscall.com%2Fmediaframe%2Fwebcast.html%3Fwebcastid%3Dgbu0MZxe" target="_blank" rel="nofollow">https://event.choruscall.com/mediaframe/webcast.html?webcastid=gbu0MZxe</a>, or via the webcast link on the Investor Relations http://www.streetinsider.com/PRNewswire/Castle+Biosciences+to+Release+Second+Quarter+2026+Financial+Results+and+Host+Webcast+on+Thursday%2C+July+30%2C+2026/26749912.html Thu, 09 Jul 2026 07:00:00 -0400 CSTL O.26012332 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CASTLE+BIOSCIENCES+INC++++For%3A+Jul+01++Filed+by%3A+Oelschlager+Kristen+M/26735868.html si-local-file:///var/storage/secattach/20260706/26735868.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CASTLE+BIOSCIENCES+INC++++For%3A+Jul+01++Filed+by%3A+Oelschlager+Kristen+M/26735868.html Mon, 06 Jul 2026 16:25:00 -0400 CSTL O.26012332 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CASTLE+BIOSCIENCES+INC++++For%3A+Jul+01++Filed+by%3A+Oelschlager+Kristen+M/26735868.html si-local-file:///var/storage/secattach/20260706/26735868.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CASTLE+BIOSCIENCES+INC++++For%3A+Jul+01++Filed+by%3A+Oelschlager+Kristen+M/26735868.html Mon, 06 Jul 2026 16:25:00 -0400 CSTL O.26012332 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CASTLE+BIOSCIENCES+INC++++For%3A+Jul+01++Filed+by%3A+MAETZOLD+DEREK+J/26735876.html si-local-file:///var/storage/secattach/20260706/26735876.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CASTLE+BIOSCIENCES+INC++++For%3A+Jul+01++Filed+by%3A+MAETZOLD+DEREK+J/26735876.html Mon, 06 Jul 2026 16:25:00 -0400 CSTL O.26012332 http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CASTLE+BIOSCIENCES+INC++++For%3A+Jul+01++Filed+by%3A+MAETZOLD+DEREK+J/26735876.html si-local-file:///var/storage/secattach/20260706/26735876.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++CASTLE+BIOSCIENCES+INC++++For%3A+Jul+01++Filed+by%3A+MAETZOLD+DEREK+J/26735876.html Mon, 06 Jul 2026 16:25:00 -0400 CSTL O.26012332 http://www.streetinsider.com/SEC+Filings/Form++144++++++++CASTLE+BIOSCIENCES+INC+++++++++++++++++Filed+by%3A+MAETZOLD+DEREK+J/26722272.html si-local-file:///var/storage/secattach/20260701/26722272.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++CASTLE+BIOSCIENCES+INC+++++++++++++++++Filed+by%3A+MAETZOLD+DEREK+J/26722272.html Wed, 01 Jul 2026 17:36:00 -0400 CSTL O.26012332 http://www.streetinsider.com/SEC+Filings/Form++144++++++++CASTLE+BIOSCIENCES+INC+++++++++++++++++Filed+by%3A+MAETZOLD+DEREK+J/26722272.html si-local-file:///var/storage/secattach/20260701/26722272.html http://www.streetinsider.com/SEC+Filings/Form++144++++++++CASTLE+BIOSCIENCES+INC+++++++++++++++++Filed+by%3A+MAETZOLD+DEREK+J/26722272.html Wed, 01 Jul 2026 17:36:00 -0400 CSTL O.26012332 http://www.streetinsider.com/Corporate+News/Castle+Biosciences+melanoma+test+outperforms+MIA+nomogram+in+study/26692828.html <p>Castle Biosciences (Nasdaq: CSTL) announced the publication of a prospective, multicenter study in <em>Dermatology and Therapy</em> showing that its DecisionDx-Melanoma i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma Institute Australia (MIA) nomogram.</p><p>The study evaluated 912 patients enrolled in the multicenter DECIDE study and compared the i31-SLNB result, which integrates a 31-gene expression profile score with clinicopathologic factors, against the MIA nomogram, which uses clinicopathologic factors alone.</p><p>Patients classified as low risk by the i31-SLNB had an observed SLN positivity rate of 2.6%, falling below the National Comprehensive Cancer http://www.streetinsider.com/Corporate+News/Castle+Biosciences+melanoma+test+outperforms+MIA+nomogram+in+study/26692828.html Thu, 25 Jun 2026 16:31:38 -0400 CSTL http://www.streetinsider.com/FDA/Castle+Biosciences+melanoma+test+outperforms+MIA+nomogram+in+study/26692828.html <p>Castle Biosciences (Nasdaq: CSTL) announced the publication of a prospective, multicenter study in <em>Dermatology and Therapy</em> showing that its DecisionDx-Melanoma i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma Institute Australia (MIA) nomogram.</p><p>The study evaluated 912 patients enrolled in the multicenter DECIDE study and compared the i31-SLNB result, which integrates a 31-gene expression profile score with clinicopathologic factors, against the MIA nomogram, which uses clinicopathologic factors alone.</p><p>Patients classified as low risk by the i31-SLNB had an observed SLN positivity rate of 2.6%, falling below the National Comprehensive Cancer http://www.streetinsider.com/FDA/Castle+Biosciences+melanoma+test+outperforms+MIA+nomogram+in+study/26692828.html Thu, 25 Jun 2026 16:31:38 -0400 CSTL http://www.streetinsider.com/Press+Releases/DecisionDx%C2%AE-Melanoma%27s+i31-SLNB+Outperforms+MIA+Nomogram+in+Identifying+Patients+Who+May+Safely+Forgo+Sentinel+Lymph+Node+Biopsy/26692771.html <div class="xn-content"> <p class="prntac"><i>Newly published prospective study</i> <i>shows DecisionDx-Melanoma's i31-SLNB test result more accurately identifies patients at low and high risk of sentinel lymph node (SLN) positivity than the Melanoma Institute Australia (MIA) nomogram</i></p><p class="prntac"><i>Patients classified as low risk by the i31-SLNB result had a 2.6% observed SLN positivity rate, falling well below the National Comprehensive Cancer Network (NCCN)</i> <i>5%</i> <i>threshold used to consider avoiding sentinel lymph node biopsy (SLNB), compared with a 5.8% observed positivity rate for the MIA nomogram</i></p><p><span class="legendSpanClass"><location value="LU/us.tx.friood" idsrc="xmltag.org" >FRIENDSWOOD, Texas</location></span>, <span class="legendSpanClass"><chron>June 25, 2026</chron></span> /PRNewswire/ -- <span value="NASDAQ-NMS:CSTL" idsrc="xmltag.org" >Castle Biosciences, Inc.</span> (Nasdaq: CSTL), a http://www.streetinsider.com/Press+Releases/DecisionDx%C2%AE-Melanoma%27s+i31-SLNB+Outperforms+MIA+Nomogram+in+Identifying+Patients+Who+May+Safely+Forgo+Sentinel+Lymph+Node+Biopsy/26692771.html Thu, 25 Jun 2026 16:30:00 -0400 A.01556100 CSTL O.26012332 O.37830347